# Evaluation of 64Cu-DOTA-U3-1287 in Subjects With Advanced Solid Tumors

> **NCT01479023** · PHASE1 · TERMINATED · sponsor: **Washington University School of Medicine** · enrollment: 12 (actual)

## Conditions studied

- Carcinoma
- Sarcoma
- Lymphoma

## Interventions

- **DRUG:** 64Cu-DOTA-U3-1287
- **DRUG:** U3-1287 (unlabeled)

## Key facts

- **NCT ID:** NCT01479023
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-04
- **Primary completion:** 2013-01
- **Final completion:** 2013-03
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** treatment was not working
- **Last updated:** 2013-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01479023

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01479023, "Evaluation of 64Cu-DOTA-U3-1287 in Subjects With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01479023. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*